Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 487
- Registration Number
- NCT04871711
- Locations
- 🇬🇧
LEO Investigational Site, London, United Kingdom
Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT04807751
- Locations
- 🇩🇪
Bioskin Research Center Dermatology, Hamburg, Germany
A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 101
- Registration Number
- NCT04674826
- Locations
- 🇩🇪
LEO Pharma Investigational Site, Berlin, Germany
Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 106
- Registration Number
- NCT04587453
- Locations
- 🇯🇵
LEO Investigational Site, Fukuoka, Japan
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 113
- Registration Number
- NCT04533737
- Locations
- 🇬🇧
LEO Pharma Investigational Site, London, United Kingdom
🇬🇧LEO Pharma investigational site, Leeds, West Yorkshire, United Kingdom
🇬🇷LEO Pharma Investigational Site 2, Thessaloníki, Greece
Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 35
- Registration Number
- NCT04361136
- Locations
- 🇩🇪
Bioskin Research Center Dermatology, Hamburg, Germany
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT04305327
- Locations
- 🇪🇸
LEO Pharma Investigational Site, Valencia, Spain
🇩🇪LEO Pharm Investigational Site, Mainz, Germany
Adjusted Brodalumab Dose Compared with Standard Brodalumab Dose in Subjects with Moderate-to-severe Plaque Psoriasis and ≥120 Kg Body Weight
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 385
- Registration Number
- NCT04306315
- Locations
- 🇬🇧
LEO Pharma Investigational Site, Shipley, United Kingdom
TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction
Completed
- Conditions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1218
- Registration Number
- NCT04202445
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- LEO Pharma
- Registration Number
- NCT03995550
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath